Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetic Study of Pembrolizumab in NSCLC and HNSCC
NCT07633613Phase 4Not yet recruiting
- Sponsor
- Centre Antoine Lacassagne
- Start
- Oct 2026
- Primary completion
- May 2029
01
Overview
A Phase 4 trial of pembrolizumab in non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), sponsored by Centre Antoine Lacassagne. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT07633613.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07633613.